Drug Trial Radar · NCT06086613
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Oct 3, 2023
Primary completion
Oct 17, 2024
Study completion Oct 17, 2024
Sponsor
- Lead sponsor
- Angitia Incorporated LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.
Conditions
- Osteogenesis Imperfecta
Interventions
AGA2115Drug
In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort). In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.
PlaceboDrug
In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort). In Part B, participants will receive multiple doses of placebo administered as a SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Orange County Research Center
Lake Forest, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.